Skip to main content

Table 7 Sites of cancer recurrence in lung adenocarcinoma patients with different initial afatinib dosages

From: Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations

Recurrence All patients Afatinib 30 mg daily Afatinib 40 mg daily P value
Number of recurrent sites -n (%)     0.3222
 No recurrence 89 (50%) 47 (46%) 42 (55%)  
 1 site 67 (37%) 43 (42%) 24 (31%)  
  ≥ 2 sites 23 (13%) 12 (12%) 11 (14%)  
Details of recurrent sites
 Central nervous system 34 (19%) 18 (18%) 16 (21%) 0.5969
 Lung 38 (21%) 23 (23%) 15 (19%) 0.6192
 Pleura or pleural effusion 16 (9%) 11 (11%) 5 (6%) 0.3191
 Bone 16 (9%) 13 (13%) 3 (4%) 0.0399
 Liver 8 (4%) 5 (5%) 3 (4%) 0.7471
 Other sites 7 (4%) 2 (2%) 5 (6%) 0.1214